Brought to you by 
Ceptaris raises $10mm through Series D-1 round
19 Mar 2013
Executive Summary
Ceptaris Therapeutics Inc. (spec pharma focused on cancer) raised $10mm through its Series D-1 round. New investor Third Point was joined by returning backers Vivo Ventures, Palo Alto Investors, Burrill & Co., Aperture Venture Partners, Osage, BioAdvance, and 26 other undisclosed investors. Some of the proceeds will be used to address a Complete Response Letter recently received by the FDA regarding the NDA for Ceptaris' mechlorethamine gel, which is in development for the early stages of a type of cutaneous T-cell lymphoma called mycosis fungoides.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Topical Delivery
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ceptaris raises $10mm through Series D-1 round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice